{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T00:20:37Z","timestamp":1793578837292,"version":"4.5.0"},"reference-count":53,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,5,26]],"date-time":"2023-05-26T00:00:00Z","timestamp":1685059200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurobiology of Disease"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1016\/j.nbd.2023.106175","type":"journal-article","created":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T08:03:55Z","timestamp":1685606635000},"page":"106175","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":35,"special_numbering":"C","title":["Head-to-head comparison of plasma p-tau181, p-tau231 and glial fibrillary acidic protein in clinically unimpaired elderly with three levels of APOE4-related risk for Alzheimer's disease"],"prefix":"10.1016","volume":"183","author":[{"given":"Anniina","family":"Snellman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura L.","family":"Ekblad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas J.","family":"Ashton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas K.","family":"Karikari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Lantero-Rodriguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elina","family":"Pietil\u00e4","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikko","family":"Koivum\u00e4ki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Semi","family":"Helin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mira","family":"Karrasch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik","family":"Zetterberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaj","family":"Blennow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juha O.","family":"Rinne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.nbd.2023.106175_bb0005","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1038\/s41582-021-00616-3","article-title":"Blood GFAP as an emerging biomarker in brain and spinal cord disorders","author":"Abdelhak","year":"2022","journal-title":"Nat. Rev. Neurol. 18"},{"key":"10.1016\/j.nbd.2023.106175_bb0010","doi-asserted-by":"crossref","DOI":"10.1038\/s41591-022-02074-w","article-title":"Differential roles of A\u03b242\/40, p-tau231 and p-tau217 for Alzheimer\u2019s trial selection and disease monitoring","volume":"28","author":"Ashton","year":"2022","journal-title":"Nat. Med."},{"issue":"5","key":"10.1016\/j.nbd.2023.106175_bb0015","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1002\/alz.12841","article-title":"Plasma and CSF biomarkers in a memory clinic: head-to-head comparison of phosphorylated tau immunoassays","volume":"19","author":"Ashton","year":"2023","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.nbd.2023.106175_bb0020","doi-asserted-by":"crossref","DOI":"10.1007\/s00401-021-02275-6","article-title":"Plasma p-tau231: a new biomarker for incipient Alzheimer\u2019s disease pathology","volume":"141","author":"Ashton","year":"2021","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.nbd.2023.106175_bb0025","first-page":"76","article-title":"Cerebrospinal fluid p-tau231 as an early indicator of emerging pathology in Alzheimer\u2019s disease","author":"Ashton","year":"2022","journal-title":"EBioMedicine"},{"key":"10.1016\/j.nbd.2023.106175_bb0030","article-title":"Plasma glial fibrillary acidic protein levels differ along the spectra of amyloid burden and clinical disease stage","volume":"78","author":"Asken","year":"2020","journal-title":"J. Alzheimer\u2019s Dis.: JAD"},{"key":"10.1016\/j.nbd.2023.106175_bb0035","first-page":"14","article-title":"Diagnostic value of plasma p-tau181, NfL, and GFAP in a clinical setting cohort of prevalent neurodegenerative dementias","author":"Baiardi","year":"2022","journal-title":"Alzheimers Res. Ther."},{"key":"10.1016\/j.nbd.2023.106175_bb0040","first-page":"13","article-title":"Clinical and analytical comparison of six Simoa assays for plasma P-tau isoforms P-tau181, P-tau217, and P-tau231","author":"Bayoumy","year":"2021","journal-title":"Alzheimers Res. Ther."},{"key":"10.1016\/j.nbd.2023.106175_bb0045","first-page":"78","article-title":"Differences between plasma and cerebrospinal fluid glial fibrillary acidic protein levels across the Alzheimer disease continuum","author":"Benedet","year":"2021","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.nbd.2023.106175_bb0050","first-page":"11","article-title":"Plasma glial fibrillary acidic protein is elevated in cognitively normal older adults at risk of Alzheimer\u2019s disease","author":"Chatterjee","year":"2021","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.nbd.2023.106175_bb0055","first-page":"18","article-title":"Diagnostic and prognostic plasma biomarkers for preclinical Alzheimer\u2019s disease","author":"Chatterjee","year":"2022","journal-title":"Alzheimer\u2019s & Dement.: J. Alzheimer\u2019s Assoc."},{"key":"10.1016\/j.nbd.2023.106175_bb0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.neulet.2019.134306","article-title":"Peripheral versus central nervous system APOE in Alzheimer\u2019s disease: interplay across the blood-brain barrier","volume":"708","author":"Chernick","year":"2019","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.nbd.2023.106175_bb0065","first-page":"13","article-title":"Plasma glial fibrillary acidic protein detects Alzheimer pathology and predicts future conversion to Alzheimer dementia in patients with mild cognitive impairment","author":"Cicognola","year":"2021","journal-title":"Alzheimers Res. Ther."},{"key":"10.1016\/j.nbd.2023.106175_bb0070","first-page":"8","article-title":"Aducanumab: appropriate use recommendations","author":"Cummings","year":"2021","journal-title":"J. Prevent. Alzheimer\u2019s Dis."},{"key":"10.1016\/j.nbd.2023.106175_bb0075","doi-asserted-by":"crossref","DOI":"10.1016\/S1474-4422(21)00066-1","article-title":"Clinical diagnosis of Alzheimer\u2019s disease: recommendations of the international working group","volume":"20","author":"Dubois","year":"2021","journal-title":"Lancet Neurol."},{"issue":"1","key":"10.1016\/j.nbd.2023.106175_bb0080","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2212948","article-title":"Lecanemab in early Alzheimer\u2019s disease","volume":"388","author":"van Dyck","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.nbd.2023.106175_bb0085","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000005214","article-title":"Midlife insulin resistance, APOE genotype, and late-life brain amyloid accumulation","volume":"90","author":"Ekblad","year":"2018","journal-title":"Neurology"},{"key":"10.1016\/j.nbd.2023.106175_bb0090","doi-asserted-by":"crossref","DOI":"10.1016\/j.jalz.2019.09.004","article-title":"Plasma biomarkers of astrocytic and neuronal dysfunction in early- and late-onset Alzheimer\u2019s disease","volume":"16","author":"Elahi","year":"2020","journal-title":"Alzheimer\u2019s & Dement.: J. Alzheimer\u2019s Assoc."},{"key":"10.1016\/j.nbd.2023.106175_bb0095","doi-asserted-by":"crossref","DOI":"10.1038\/s41593-020-00783-4","article-title":"Reactive astrocyte nomenclature, definitions, and future directions","volume":"24","author":"Escartin","year":"2021","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.nbd.2023.106175_bb0100","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000004643","article-title":"In vivo staging of regional amyloid deposition","volume":"89","author":"Grothe","year":"2017","journal-title":"Neurology"},{"key":"10.1016\/j.nbd.2023.106175_bb0105","first-page":"14","article-title":"NIA-AA research framework: toward a biological definition of Alzheimer\u2019s disease","author":"Jack","year":"2018","journal-title":"Alzheimer\u2019s & Dement.: J. Alzheimer\u2019s Assoc."},{"issue":"4","key":"10.1016\/j.nbd.2023.106175_bb0110","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1093\/brain\/awac333","article-title":"Head-to-head comparison of 10 plasma phospho-tau assays in prodromal Alzheimer\u2019s disease","volume":"146","author":"Janelidze","year":"2022","journal-title":"Brain"},{"key":"10.1016\/j.nbd.2023.106175_bb0115","first-page":"35","article-title":"C-terminally truncated forms of tau, but not full-length tau or its C-terminal fragments, are released from neurons independently of cell death","author":"Kanmert","year":"2015","journal-title":"J. Neurosci. Off. J. Soc. Neurosci."},{"key":"10.1016\/j.nbd.2023.106175_bb0120","doi-asserted-by":"crossref","DOI":"10.1016\/S1474-4422(20)30071-5","article-title":"Blood phosphorylated tau 181 as a biomarker for Alzheimer\u2019s disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts","volume":"19","author":"Karikari","year":"2020","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.nbd.2023.106175_bb0125","doi-asserted-by":"crossref","DOI":"10.1038\/s41380-020-00923-z","article-title":"Diagnostic performance and prediction of clinical progression of plasma phospho-tau181 in the Alzheimer\u2019s disease neuroimaging initiative","volume":"26","author":"Karikari","year":"2021","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.nbd.2023.106175_bb0130","first-page":"18","article-title":"Blood phospho-tau in Alzheimer disease: analysis, interpretation, and clinical utility","author":"Karikari","year":"2022","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.nbd.2023.106175_bb0135","doi-asserted-by":"crossref","DOI":"10.1161\/STROKEAHA.117.018409","article-title":"Plasma glial fibrillary acidic protein in the differential diagnosis of intracerebral hemorrhage","volume":"48","author":"Katsanos","year":"2017","journal-title":"Stroke"},{"key":"10.1016\/j.nbd.2023.106175_bb0140","article-title":"Population-based blood screening for preclinical Alzheimer\u2019s disease in a British birth cohort at age 70","volume":"144","author":"Keshavan","year":"2021","journal-title":"Brain J. Neurol."},{"key":"10.1016\/j.nbd.2023.106175_bb0145","first-page":"12","article-title":"The Alzheimer\u2019s prevention initiative composite cognitive test: a practical measure for tracking cognitive decline in preclinical Alzheimer\u2019s disease","author":"Langbaum","year":"2020","journal-title":"Alzheimers Res. Ther."},{"key":"10.1016\/j.nbd.2023.106175_bb0150","doi-asserted-by":"crossref","DOI":"10.1007\/s00401-020-02195-x","article-title":"Plasma p-tau181 accurately predicts Alzheimer\u2019s disease pathology at least 8 years prior to post-mortem and improves the clinical characterisation of cognitive decline","volume":"140","author":"Lantero Rodriguez","year":"2020","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.nbd.2023.106175_bb0155","first-page":"5","article-title":"Changes in amyloid-\u03b2 and tau in the cerebrospinal fluid of transgenic mice overexpressing amyloid precursor protein","author":"Maia","year":"2013","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.nbd.2023.106175_bb0160","doi-asserted-by":"crossref","DOI":"10.1093\/brain\/awaa286","article-title":"Longitudinal plasma p-tau217 is increased in early stages of Alzheimer\u2019s disease","volume":"143","author":"Mattsson-Carlgren","year":"2020","journal-title":"Brain J. Neurol."},{"key":"10.1016\/j.nbd.2023.106175_bb0165","doi-asserted-by":"crossref","DOI":"10.1002\/ana.26308","article-title":"Plasma p-tau231, p-tau181, PET biomarkers, and cognitive change in older adults","volume":"91","author":"Meyer","year":"2022","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.nbd.2023.106175_bb0170","first-page":"14","article-title":"Plasma phospho-tau181 increases with Alzheimer\u2019s disease clinical severity and is associated with tau- and amyloid-positron emission tomography","author":"Mielke","year":"2018","journal-title":"Alzheimer\u2019s & Dement.: J. Alzheimer\u2019s Assoc."},{"key":"10.1016\/j.nbd.2023.106175_bb0175","article-title":"Plasma p-tau231 and p-tau217 as state markers of amyloid-\u03b2 pathology in preclinical Alzheimer\u2019s disease","volume":"28","author":"Mil\u00e0-Alom\u00e0","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.nbd.2023.106175_bb0180","first-page":"78","article-title":"Longitudinal associations of blood phosphorylated Tau181 and Neurofilament light chain with neurodegeneration in Alzheimer disease","author":"Moscoso","year":"2021","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.nbd.2023.106175_bb0185","article-title":"Glial fibrillary acidic protein in serum is increased in Alzheimer\u2019s disease and correlates with cognitive impairment","volume":"67","author":"Oeckl","year":"2019","journal-title":"J. Alzheimer\u2019s Dis.: JAD"},{"key":"10.1016\/j.nbd.2023.106175_bb0190","doi-asserted-by":"crossref","DOI":"10.1001\/jama.2020.12134","article-title":"Discriminative accuracy of plasma Phospho-tau217 for Alzheimer disease vs other neurodegenerative disorders","volume":"324","author":"Palmqvist","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.nbd.2023.106175_bb0195","doi-asserted-by":"crossref","DOI":"10.1093\/brain\/awab223","article-title":"Plasma GFAP is an early marker of amyloid-\u03b2 but not tau pathology in Alzheimer\u2019s disease","volume":"144","author":"Pereira","year":"2021","journal-title":"Brain J. Neurol."},{"issue":"12","key":"10.1016\/j.nbd.2023.106175_bb0200","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1001\/jamaneurol.2022.3392","article-title":"Association of Donanemab Treatment with Exploratory Plasma Biomarkers in early symptomatic Alzheimer disease: a secondary analysis of the TRAILBLAZER-ALZ randomized clinical trial","volume":"79","author":"Pontecorvo","year":"2022","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.nbd.2023.106175_bb0205","first-page":"14","article-title":"Inflammatory plasma biomarkers in subjects with preclinical Alzheimer\u2019s disease","author":"Prins","year":"2022","journal-title":"Alzheimers Res. Ther."},{"key":"10.1016\/j.nbd.2023.106175_bb0210","doi-asserted-by":"crossref","DOI":"10.1076\/jcen.20.3.310.823","article-title":"The repeatable battery for the assessment of neuropsychological status (RBANS): preliminary clinical validity","volume":"20","author":"Randolph","year":"1998","journal-title":"J. Clin. Exp. Neuropsychol."},{"key":"10.1016\/j.nbd.2023.106175_bb0215","doi-asserted-by":"crossref","DOI":"10.1007\/s00259-021-05192-8","article-title":"Differential associations of APOE-\u03b52 and APOE-\u03b54 alleles with PET-measured amyloid-\u03b2 and tau deposition in older individuals without dementia","volume":"48","author":"Salvad\u00f3","year":"2021","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"10.1016\/j.nbd.2023.106175_bb0220","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuron.2018.02.015","article-title":"Tau kinetics in neurons and the human central nervous system","volume":"97","author":"Sato","year":"2018","journal-title":"Neuron"},{"issue":"1","key":"10.1016\/j.nbd.2023.106175_bb0225","article-title":"Association of Plasma Glial Fibrillary Acidic Protein (GFAP) with Neuroimaging of Alzheimer\u2019s Disease and Vascular Pathology","volume":"14","author":"Shir","year":"2022","journal-title":"Alzheimer\u2019s & dementia (Amsterdam, Netherlands)"},{"key":"10.1016\/j.nbd.2023.106175_bb0230","first-page":"13","article-title":"ASIC-E4: interplay of Beta-amyloid, synaptic density and Neuroinflammation in cognitively normal volunteers with three levels of genetic risk for late-onset Alzheimer\u2019s disease - study protocol and baseline characteristics","author":"Snellman","year":"2022","journal-title":"Front. Neurol."},{"key":"10.1016\/j.nbd.2023.106175_bb0235","first-page":"15","article-title":"APOE \u03b54 gene dose effect on imaging and blood biomarkers of neuroinflammation and beta-amyloid in cognitively unimpaired elderly","author":"Snellman","year":"2023","journal-title":"Alzheimers Res. Ther."},{"issue":"1","key":"10.1016\/j.nbd.2023.106175_bb0240","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1002\/alz.12614","article-title":"Association of plasma biomarkers, p-tau181, glial fibrillary acidic protein, and neurofilament light, with intermediate and long-term clinical Alzheimer\u2019s disease risk: results from a prospective cohort followed over 17 years","volume":"19","author":"Stocker","year":"2022","journal-title":"Alzheimer\u2019s & Dement.: J. Alzheimer\u2019s Assoc."},{"key":"10.1016\/j.nbd.2023.106175_bb0245","first-page":"12","article-title":"Novel tau biomarkers phosphorylated at T181, T217 or T231 rise in the initial stages of the preclinical Alzheimer\u2019s continuum when only subtle changes in A\u03b2 pathology are detected","author":"Su\u00e1rez-Calvet","year":"2020","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.nbd.2023.106175_bb0250","article-title":"Midlife insulin resistance as a predictor for late-life cognitive function and cerebrovascular lesions","volume":"72","author":"Toppala","year":"2019","journal-title":"J. Alzheimer\u2019s Dis.: JAD"},{"key":"10.1016\/j.nbd.2023.106175_bb0255","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000011612","article-title":"Association of Early \u03b2-amyloid accumulation and Neuroinflammation measured with [11C]PBR28 in elderly individuals without dementia","volume":"96","author":"Toppala","year":"2021","journal-title":"Neurology"},{"key":"10.1016\/j.nbd.2023.106175_bb0260","series-title":"Development and validation of a high-sensitivity assay for measuring p217+tau in plasma","first-page":"13","author":"Triana-Baltzer","year":"2021"},{"key":"10.1016\/j.nbd.2023.106175_bb0265","first-page":"10","article-title":"Plasma glial fibrillary acidic protein and neurofilament light chain for the diagnostic and prognostic evaluation of frontotemporal dementia","author":"Zhu","year":"2021","journal-title":"Transl. Neurodegen."}],"container-title":["Neurobiology of Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0969996123001900?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0969996123001900?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,22]],"date-time":"2024-05-22T11:38:01Z","timestamp":1716377881000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0969996123001900"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":53,"alternative-id":["S0969996123001900"],"URL":"https:\/\/doi.org\/10.1016\/j.nbd.2023.106175","relation":{},"ISSN":["0969-9961"],"issn-type":[{"value":"0969-9961","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Head-to-head comparison of plasma p-tau181, p-tau231 and glial fibrillary acidic protein in clinically unimpaired elderly with three levels of APOE4-related risk for Alzheimer's disease","name":"articletitle","label":"Article Title"},{"value":"Neurobiology of Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nbd.2023.106175","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"106175"}}